Recurrent rearrangements in prostate cancer: causes and therapeutic potential - Test2 - elhamkhani - TriplyDB

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

http://www.wikidata.org/entity/Q26851525

about

Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Clonotyping for precision oncology.Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States.

P2860

Q28817152-005E6B42-F062-4BCA-9B34-480366CC8BAC Q34252397-94BF7A76-FB58-4F23-87E0-67DB4C71904F Q35620225-7B9AE43D-2284-4535-8CFF-6EE52C1E733D Q36067301-807BCE62-0389-497B-AAD1-E5AE85317D79 Q37635618-EED3D245-E006-481B-9D9A-6A3C71B5F818 Q38614405-1C2CBFCF-02C4-497E-ABFA-DA05E865F15A Q38780013-219F4305-EEF5-445E-A060-70D3B548EF82 Q49210539-C34D0C56-84E9-4A7E-9C91-E2970E4DE1FE

P2860

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

http://www.wikidata.org/entity/Q26851525

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@ast

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@en

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@nl

type

label

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@ast

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@en

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@nl

prefLabel

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@ast

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@en

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@nl

P1433

Q26851525-4144B97F-1D60-4111-A991-A58EB122FA70

P1476

Q26851525-D53BF5A5-9CFF-4EF2-BBD0-AB7A96ABAC08

P2093

Q26851525-0B16CCA5-23F7-4A85-831B-99337E9CBC5A

Q26851525-9F6101C1-3372-4F1B-B3B0-514D73679C4E

Q26851525-CE7575DE-A9DE-4C4D-B001-65582CAE22F8

P2860

Q26851525-00B1A3EE-A9D6-4A1B-8E58-706DC54D6676

Q26851525-05793443-8C54-45C5-8E80-E1A081DD9605

Q26851525-0959D1BC-4587-466F-BAC8-EE0E31D62F81

Q26851525-0D4744BA-4856-4E30-B950-9265D16454A6

Q26851525-0E4427B7-3A10-4693-9B79-B9BBF11F9436

Q26851525-1427C071-60E1-4069-8C04-154F2DD6C2B8

Q26851525-15C49381-0049-4AE9-B2C4-7928568B640C

Q26851525-1695CB8C-D3DE-42AB-9931-91FC248A4C99

Q26851525-1B809FDC-690B-430B-B5E0-6A7F130BD83E

Q26851525-2185EEF7-C988-4BAB-86CF-FCF6C22200E8

P304

Q26851525-9C7CACAC-3C90-42DE-BA3E-5F1361CB34C1

P31

Q26851525-7689460D-75DD-4745-8F1C-ECB0BFC5A95A

P3181

Q26851525-147580A6-156F-4337-9D18-70A0FE73335A

P356

Q26851525-68787624-42CC-4778-8333-5859AB859E09

P407

Q26851525-79732383-7DAA-4B1A-B260-6EC5CA6087D3

P433

Q26851525-94B52561-63F2-4E1D-8521-9C681614EAA8

P478

Q26851525-01CF22F1-4A65-4C29-843F-586E508EC40C

P577

Q26851525-E7C933F8-069B-4F8F-8AF0-B923FB6E9683

P698

Q26851525-B56AD176-1615-4A36-8A53-481CDF4712FD

P932

Q26851525-32F77116-4CFB-48D1-98CF-A54F31C2EFA1

P3181

P356

1389450111314040006

P1433

Current Drug Targets

P1476

Recurrent rearrangements in prostate cancer: causes and therapeutic potential

@en

P2093

Feng FY

http://www.w3.org/2001/XMLSchema#string

Maher CA

http://www.w3.org/2001/XMLSchema#string

White NM

http://www.w3.org/2001/XMLSchema#string

P2860

Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

The genomic complexity of primary human prostate cancer

The role of SPINK1 in ETS rearrangement-negative prostate cancers

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

Transcriptome sequencing to detect gene fusions in cancer

P304

450-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

764916

http://www.w3.org/2001/XMLSchema#string

P356

10.2174/1389450111314040006

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23410129

http://www.w3.org/2001/XMLSchema#string

P932

3733264

http://www.w3.org/2001/XMLSchema#string